Evidence map›Paper›PMID 39569042›Full record

ArticleGates open research2024

Power calculation for mosquito bioassays: Quantifying variability in the WHO tube bioassay and developing sample size guidance for the PBO synergism assay using a Shiny application.

Frank Mechan, Giorgio Praulins, Jack Gillespie, Katherine Gleave, Annabel Murphy-Fegan, Daniel P McDermott, David Weetman, Rosemary Susan Lees

Abstract read
In one paragraph

Article in Gates open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Frank MechanInnovation To Impact (I2I), Department of Vector Biology, Liverpool, Liverpool, L35QA, UK.ORCID https://orcid.org/0000-0001-6858-7010
Giorgio PraulinsInnovation To Impact (I2I), Department of Vector Biology, Liverpool, Liverpool, L35QA, UK.ORCID https://orcid.org/0000-0003-2601-2598
Jack GillespieInnovation To Impact (I2I), Department of Vector Biology, Liverpool, Liverpool, L35QA, UK.
Katherine GleaveInnovation To Impact (I2I), Department of Vector Biology, Liverpool, Liverpool, L35QA, UK.
Annabel Murphy-FeganInnovation To Impact (I2I), Department of Vector Biology, Liverpool, Liverpool, L35QA, UK.
Daniel P McDermottVector Biology, Liverpool School of Tropical Medicine, Liverpool, England, UK.
David WeetmanVector Biology, Liverpool School of Tropical Medicine, Liverpool, England, UK.
Rosemary Susan LeesInnovation To Impact (I2I), Department of Vector Biology, Liverpool, Liverpool, L35QA, UK.ORCID https://orcid.org/0000-0002-4232-9125

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The WHO tube bioassay is a method for exposing mosquitos to determine susceptibility to insecticides, with mortality to discriminating doses <98% indicating possible resistance and <90% confirming resistance. This bioassay is also used for synergism testing to assess if susceptibility is restored by pre-exposure to the synergist piperonyl butoxide. Methods: Here we perform testing with pyrethroid-susceptible and pyrethroid-resistant Results: We show that approximately two-thirds of variation occurs between days, with the pyrethroid-susceptible strain twice as variable as the pyrethroid-resistant strain. The total number of mosquitoes in the tube and their bodyweight contributes to approximately 10% of this variability. Changes in temperature and humidity, within a climate-controlled insectary, didn't impact mortality. Using a simulation-based framework, we show that the current synergism guidelines, using a 4x4 design, can reliably detect a difference between 90% and 100% mortality (>90% power). However, as the mortality of either group gets closer to 50%, a 10% difference between groups is more difficult to reliably detect. In the worst-case scenario where the mortality of either group is 50%, the mortality difference must be >22.5% to be detected with 80% power. We provide an R shiny application to assess power for other comparisons. Conclusions: Our findings indicate that detecting synergism with the WHO tube assay is more difficult than assumed by the current WHO guidelines. Additionally, we demonstrate the value of using a Shiny application to make the outputs of simulation-based power analysis readily available to end-users, allowing them to determine the number of tubes needed to detect a given mortality difference.

Indexed as

AnophelesBiological AssayInsecticide ResistanceInsecticidesPiperonyl ButoxideAnimalsDrug SynergismMosquito ControlPyrethrinsSample SizeWorld Health OrganizationInsecticidesPiperonyl ButoxidePyrethrinsbioassayinsecticide resistanceMalariamosquitopower analysisresistance monitoringsample sizevariabilityvector control

Identifiers

PMID39569042
PMCPMC11576473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.